Lancet:芬氟拉明用于Dravet综合征的治疗

2019-12-18 MedSci MedSci原创

研究认为,芬氟拉明可显著降低Dravet综合征患者痉挛性发作频率,且总体耐受性良好

Dravet综合征是一种罕见的、难治性的发育性癫痫性脑病,其特点是多种类型的频繁、致残性癫痫发作。芬氟拉明在光敏性癫痫和Dravet综合征的观察研究中有抗癫痫作用。本研究旨在评价芬氟拉明治疗Dravet综合征的疗效和安全性。

具有Dravet综合征患者参与研究。在为期6周的观察期后,建立基线每月惊厥发作频率(MCSF;抽搐发作定义为半阵挛、强直、阵挛、强直阵挛性、大面积强直阵挛和有明显运动体征的局灶性发作),在现有抗癫痫治疗基础上,随机接受安慰剂或芬氟拉明(每日0.2或0.7 mg/kg)。研究的主要结果是治疗期间与基线相比,癫痫发作的月平均频率变化。

119例患者参与研究,平均年龄9.0岁,男性64例,其中芬氟拉明0.2mg/kg/d组39例、芬氟拉明0.7mg/kg/d组40例、安慰剂组40例。治疗期间芬氟拉明0.7mg/kg组发作次数中位数下降74.9%(从每28天20.7次发作减少到每28天4.7次发作),芬氟拉明0.2mg/kg组下降42.3%(从每28天17.5次发作减少到每28天12.6次发作),安慰剂组为19.2%(中位数从每28天27.3次下降到每28天22.0次)。达到了主要疗效终点,芬氟拉明0.7mg/kg/天,与安慰剂相比,平均MCSF下降62.3%;芬氟拉明0.2mg/kg/天,平均MCSF比安慰剂降低32.4%。最常见的不良反应是食欲下降、腹泻、疲劳、嗜睡、嗜睡和体重下降。

研究认为,芬氟拉明可显著降低Dravet综合征患者痉挛性发作频率,且总体耐受性良好。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1830381, encodeId=ccc8183038127, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Thu Feb 27 17:35:00 CST 2020, time=2020-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1776676, encodeId=a21a1e7667643, content=<a href='/topic/show?id=4abd8691114' target=_blank style='color:#2F92EE;'>#芬氟拉明#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86911, encryptionId=4abd8691114, topicName=芬氟拉明)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=679c38990886, createdName=zhangfenasdf, createdTime=Sat May 30 21:35:00 CST 2020, time=2020-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=378185, encodeId=18913e8185a9, content=了解一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Wed Jan 15 21:58:00 CST 2020, time=2020-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1361265, encodeId=cdc81361265b8, content=<a href='/topic/show?id=73556238a1' target=_blank style='color:#2F92EE;'>#Dravet综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6238, encryptionId=73556238a1, topicName=Dravet综合征)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7460166, createdName=zhang92560, createdTime=Fri Dec 20 09:35:00 CST 2019, time=2019-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1431711, encodeId=c3971431e11d0, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Fri Dec 20 09:35:00 CST 2019, time=2019-12-20, status=1, ipAttribution=)]
    2020-02-27 howi
  2. [GetPortalCommentsPageByObjectIdResponse(id=1830381, encodeId=ccc8183038127, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Thu Feb 27 17:35:00 CST 2020, time=2020-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1776676, encodeId=a21a1e7667643, content=<a href='/topic/show?id=4abd8691114' target=_blank style='color:#2F92EE;'>#芬氟拉明#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86911, encryptionId=4abd8691114, topicName=芬氟拉明)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=679c38990886, createdName=zhangfenasdf, createdTime=Sat May 30 21:35:00 CST 2020, time=2020-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=378185, encodeId=18913e8185a9, content=了解一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Wed Jan 15 21:58:00 CST 2020, time=2020-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1361265, encodeId=cdc81361265b8, content=<a href='/topic/show?id=73556238a1' target=_blank style='color:#2F92EE;'>#Dravet综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6238, encryptionId=73556238a1, topicName=Dravet综合征)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7460166, createdName=zhang92560, createdTime=Fri Dec 20 09:35:00 CST 2019, time=2019-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1431711, encodeId=c3971431e11d0, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Fri Dec 20 09:35:00 CST 2019, time=2019-12-20, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1830381, encodeId=ccc8183038127, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Thu Feb 27 17:35:00 CST 2020, time=2020-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1776676, encodeId=a21a1e7667643, content=<a href='/topic/show?id=4abd8691114' target=_blank style='color:#2F92EE;'>#芬氟拉明#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86911, encryptionId=4abd8691114, topicName=芬氟拉明)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=679c38990886, createdName=zhangfenasdf, createdTime=Sat May 30 21:35:00 CST 2020, time=2020-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=378185, encodeId=18913e8185a9, content=了解一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Wed Jan 15 21:58:00 CST 2020, time=2020-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1361265, encodeId=cdc81361265b8, content=<a href='/topic/show?id=73556238a1' target=_blank style='color:#2F92EE;'>#Dravet综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6238, encryptionId=73556238a1, topicName=Dravet综合征)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7460166, createdName=zhang92560, createdTime=Fri Dec 20 09:35:00 CST 2019, time=2019-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1431711, encodeId=c3971431e11d0, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Fri Dec 20 09:35:00 CST 2019, time=2019-12-20, status=1, ipAttribution=)]
    2020-01-15 wxl882001

    了解一下

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1830381, encodeId=ccc8183038127, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Thu Feb 27 17:35:00 CST 2020, time=2020-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1776676, encodeId=a21a1e7667643, content=<a href='/topic/show?id=4abd8691114' target=_blank style='color:#2F92EE;'>#芬氟拉明#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86911, encryptionId=4abd8691114, topicName=芬氟拉明)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=679c38990886, createdName=zhangfenasdf, createdTime=Sat May 30 21:35:00 CST 2020, time=2020-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=378185, encodeId=18913e8185a9, content=了解一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Wed Jan 15 21:58:00 CST 2020, time=2020-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1361265, encodeId=cdc81361265b8, content=<a href='/topic/show?id=73556238a1' target=_blank style='color:#2F92EE;'>#Dravet综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6238, encryptionId=73556238a1, topicName=Dravet综合征)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7460166, createdName=zhang92560, createdTime=Fri Dec 20 09:35:00 CST 2019, time=2019-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1431711, encodeId=c3971431e11d0, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Fri Dec 20 09:35:00 CST 2019, time=2019-12-20, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1830381, encodeId=ccc8183038127, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Thu Feb 27 17:35:00 CST 2020, time=2020-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1776676, encodeId=a21a1e7667643, content=<a href='/topic/show?id=4abd8691114' target=_blank style='color:#2F92EE;'>#芬氟拉明#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86911, encryptionId=4abd8691114, topicName=芬氟拉明)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=679c38990886, createdName=zhangfenasdf, createdTime=Sat May 30 21:35:00 CST 2020, time=2020-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=378185, encodeId=18913e8185a9, content=了解一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Wed Jan 15 21:58:00 CST 2020, time=2020-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1361265, encodeId=cdc81361265b8, content=<a href='/topic/show?id=73556238a1' target=_blank style='color:#2F92EE;'>#Dravet综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6238, encryptionId=73556238a1, topicName=Dravet综合征)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7460166, createdName=zhang92560, createdTime=Fri Dec 20 09:35:00 CST 2019, time=2019-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1431711, encodeId=c3971431e11d0, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Fri Dec 20 09:35:00 CST 2019, time=2019-12-20, status=1, ipAttribution=)]

相关资讯

面包袋夹竟然在15岁男孩的体内至少呆了2年——案例报道

患者男,15岁,严重智力低下,患有Dravet综合征(DS;严重的遗传性癫痫性脑病,即婴儿重症肌阵挛癫痫),因“急性胃肠炎”就诊急诊。 腹部X线片(A):右下象限可见异常密度影。 2年前患者因急性腹泻,行影像学检查,发现了相同的右下象限异常密度影。但上次患者的腹泻很快好转。 这两年来,患者否认发烧、水样腹泻、血便或体重减轻等症状。否认手术史。 此次入院查体一切正常,

GW大麻二酚美国获批又迈进一大步

GW Pharma公司的大麻提取物大麻二酚(Epidiolex)很可能在美国批准用于治疗两种罕见且难治的儿童型发作性癫痫:Lennox-Gastaut综合症(LGS)和Dravet综合征(DS)相关的癫痫发作。

NEJM:大麻可改善Dravet综合征患者病情

对于Dravet综合征患者,大麻可减少惊厥发作频率但不良事件发生率高

EPX-100治疗Dravet综合征

Epygenix是一家开发Dravet综合症精准药物的生物制药公司,近日宣布,已向FDA提交了EPX-100的研究性新药申请(IND)和快速通道申请,用于治疗Dravet综合征患者。

美国为Dravet综合征提供了新的治疗方案

美国监管机构已批准Biocodex的Diacomit用于治疗与Dravet综合征(DS)相关的癫痫发作,这是一种罕见且难以治疗的癫痫形式。该决定允许医生给服用氯巴嗪的两岁以上的病人开这种药。批准是基于两项多中心安慰剂对照试验,STICLO France和STICLO Italy,这两项试验的主要疗效终点都是应答率,定义为在全身性阵挛或强直性阵挛发作频率(每30天)下降超过50%的患者数量。在STI